A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Nektar Therapeutics stock. As of the latest transaction made, Renaissance Technologies LLC holds 3,327,633 shares of NKTR stock, worth $4.36 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
3,327,633
Previous 3,313,833 0.42%
Holding current value
$4.36 Million
Previous $4.11 Million 5.26%
% of portfolio
0.01%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$1.11 - $1.48 $15,318 - $20,424
13,800 Added 0.42%
3,327,633 $4.33 Million
Q2 2024

Aug 09, 2024

SELL
$0.9 - $1.83 $1.18 Million - $2.39 Million
-1,306,848 Reduced 28.28%
3,313,833 $4.11 Million
Q1 2024

May 13, 2024

SELL
$0.49 - $0.96 $345,349 - $676,602
-704,794 Reduced 13.23%
4,620,681 $4.32 Million
Q4 2023

Feb 13, 2024

BUY
$0.42 - $0.57 $763,893 - $1.04 Million
1,818,794 Added 51.87%
5,325,475 $3.01 Million
Q3 2023

Nov 14, 2023

SELL
$0.51 - $1.05 $298,350 - $614,250
-585,000 Reduced 14.3%
3,506,681 $2.09 Million
Q2 2023

Aug 11, 2023

BUY
$0.53 - $1.03 $576,632 - $1.12 Million
1,087,985 Added 36.22%
4,091,681 $2.35 Million
Q1 2023

May 12, 2023

BUY
$0.64 - $3.15 $1.85 Million - $9.09 Million
2,886,585 Added 2464.83%
3,003,696 $2.11 Million
Q4 2022

Feb 13, 2023

BUY
$2.03 - $4.28 $237,735 - $501,235
117,111 New
117,111 $265,000
Q3 2019

Nov 13, 2019

SELL
$16.91 - $36.27 $5.53 Million - $11.9 Million
-327,048 Closed
0 $0
Q2 2019

Aug 12, 2019

BUY
$31.0 - $36.3 $3.77 Million - $4.41 Million
121,600 Added 59.19%
327,048 $11.6 Million
Q1 2019

May 14, 2019

SELL
$31.58 - $46.35 $6.21 Million - $9.11 Million
-196,500 Reduced 48.89%
205,448 $6.9 Million
Q4 2018

Feb 13, 2019

BUY
$30.43 - $56.65 $12.2 Million - $22.8 Million
401,948 New
401,948 $13.2 Million

Others Institutions Holding NKTR

About NEKTAR THERAPEUTICS


  • Ticker NKTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,404,992
  • Market Cap $246M
  • Description
  • Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
More about NKTR
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.